Keywords: Novartis, Idenix Pharma, Telbivudine, Hepatitis C, Hepatitis B, Collaboration restructuring
Novartis restructures deal with Idenix Pharmaceuticals
Article | 01 August 2012
USA-based Idenix Pharmaceuticals (Nasdaq: IDIX) says that Swiss drug major Novartis (NOVN: VX) has restructured its commercialization collaboration with the ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Is failure to adopt business process management putting the pharma industry at risk?
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
